-
Mashup Score: 0
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases. The trial will involve the use of Allogene Therapeutics’ Dagger technology, which aims to reduce, or avoid entirely, the need for pre-treatment
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 6TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - 8 day(s) ago
MaxCyte’s technology will support TG Therapeutics’ efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease MaxCyte's technology will support @TGTherapeutics' efforts to develop a CD19 CAR T cell therapy program for #autoimmune diseases. @MaxCyte_info https://t.co/mX9Mzp9WlQ
-
-
Mashup Score: 0Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease - MedCity News - 2 month(s) ago
The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet-
.@nuvigtx Nabs $161M for Better Approach to #Autoimmune Disease; first target is chronic inflammatory demyelinating polyneuropathy, which can be treated with blockbuster drug, Argenx. Nuvig aims to show its drug can offer a better way to treat this diz. https://t.co/XkIC43dDqo
-
-
Mashup Score: 0The ACR and CHEST Release 2 New ILD Guidelines - The Rheumatologist - 6 month(s) ago
Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).
Source: www.the-rheumatologist.orgCategories: General Medicine News, General Journals & SocietTweet-
Working in conjunction with @accpchest, @ACRheum released 2 new guidelines on the screening, monitoring and treatment of patients with interstitial lung disease secondary to systemic #autoimmune rheumatic diseases. Read the article in The Rheumatologist: https://t.co/FpJMso4izv https://t.co/uHJQ0iKKRS
-
-
Mashup Score: 1CAR T-cell therapy brings sustained, drug-free remission in three autoimmune diseases - 8 month(s) ago
Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.“Although antibody-based B-cell targeting certainly improved treatment of autoimmune disease, achieving long-lasting drug-free remission has proven elusive,” Fabian
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💥Single injections of CD19 CAR T-cell therapy brought long-lasting remission to 15 patients with three different #autoimmune diseases, according to new data in @NEJM. Find out more at Healio 🔽 https://t.co/2qBjKtte5h
-
-
Mashup Score: 1CAR T-cell therapy brings sustained, drug-free remission in three autoimmune diseases - 9 month(s) ago
Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.“Although antibody-based B-cell targeting certainly improved treatment of autoimmune disease, achieving long-lasting drug-free remission has proven elusive,” Fabian
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💥Single injections of CD19 CAR T-cell therapy brought long-lasting remission to 15 patients with three different #autoimmune diseases, according to new data in @NEJM. Find out more at Healio 🔽 https://t.co/2qBjKtte5h
-
-
Mashup Score: 1CAR T-cell therapy brings sustained, drug-free remission in three autoimmune diseases - 10 month(s) ago
Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.“Although antibody-based B-cell targeting certainly improved treatment of autoimmune disease, achieving long-lasting drug-free remission has proven elusive,” Fabian
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💥Single injections of CD19 CAR T-cell therapy brought long-lasting remission to 15 patients with three different #autoimmune diseases, according to new data in @NEJM. Find out more at Healio 🔽 https://t.co/2qBjKtte5h
-
-
Mashup Score: 21Georg Schett - 10 month(s) ago
Find out why Georg Schett is on the TIME100 Health list.
Source: TIME.comCategories: General Medicine News, RheumatologyTweet-
🏆Dr. Georg Schett's pioneering work in CAR-T for #autoimmune disease has landed him among the TIME100 Most Influential People in Health “Not only are the patients in drug-free remission, but I believe many are cured of their autoimmune disease," he said https://t.co/Rj7FpkluNg
-
-
Mashup Score: 0Synergy in Science: Innovations in Autoimmune Disease Research and Care - 10 month(s) ago
This symposium is sponsored by the National Institutes of Health (NIH), Office of Research on Women’s Health (ORWH), and the title of this year’s symposium is “Synergy in Science: Innovations in Autoimmune Disease Research and Care.” The symposium will discuss the convergence of cutting-edge…
Source: www.federalregister.govCategories: General Medicine News, RheumatologyTweet-
Read all about it! The 8th Annual Vivian Pinn Symposium is in the Federal Register! Join us on May 15th for an afternoon of science and spectacular #autoimmune stories @NIH_ORWH https://t.co/BFfrkslJUW
-
-
Mashup Score: 7Source of surging autoimmunity may lie in ‘a thousand cuts’ - 11 month(s) ago
The common consensus for some time has been that the prevalence of autoimmunity and autoimmune diseases has been on the rise.Decidedly less common, however, is a widely accepted explanation of why this is occurring.
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
The common consensus is that the prevalence of #autoimmune diseases is rising. But is there any answer why? 🔍In our cover story this month, learn more from Dr. Frederick Miller, Dr. Andrew Wang, Dr. Anca Askanase and @CCalabreseDO 👇 https://t.co/mxayOSIKiZ
-
🚨 @US_FDA accepted an IND for a new CAR-T therapy for #autoimmune diseases that may not require lymphodepletion, taking down a potential barrier to treatment Healio has the details, with bonus thoughts from Dr. Joan Merrill @OMRF ⬇️ https://t.co/0Ky2qRLgPf